雷鲁戈利克斯

Name: 雷鲁戈利克斯
Brand: 济南圣和化工有限公司

CAS 737789-87-6C29H27F2N7O5SMW 623.6

本页收录雷鲁戈利克斯，CAS 登记号为 737789-87-6，分子式 C29H27F2N7O5S，分子量 623.6，归类于医药中间体及原料药。作为主营产品之一，济南圣和化工有限公司可提供从公斤级到吨级的稳定供货，随货附 COA 与质检资料。

产品概览

CAS号	737789-87-6
分子式	C29H27F2N7O5S
分子量	623.6
LogP	1.69
纯度	按批次COA提供(不公开发布)
包装	按订单/批次确认(不公开发布)
应用领域	医药中间体及原料药
类别	医药中间体及原料药

应用领域

医药中间体及原料药

雷鲁戈利克斯在医药中间体及原料药领域使用广泛。采购前请确认纯度等级与包装形式，以批次 COA 为验收依据。

包装与储存

包装规格按订单/批次确认(不公开发布)

纯度规格按批次COA提供(不公开发布)

储存条件密封、阴凉干燥处保存

运输常规化工运输

样品可协商提供

交期现货/按订单安排

供货能力：雷鲁戈利克斯备有现货，包装形式为按订单/批次确认(不公开发布)。我们支持对公转账并开具增值税发票，山东省内可安排快速配送，省外按物流时效发货，具体请联系 info@591daili.com。

质量与文件

每批产品随货提供 COA（分析证书）；可按需提供 MSDS/技术数据表及第三方检测报告。纯度与包装以批次 COA 及订单确认为准。

关于供应商

作为化工原料供应服务商，济南圣和化工有限公司长期服务于化工贸易、食品添加、医药中间体、日化原料等行业的采购需求。除雷鲁戈利克斯外，您还可以在站内按 CAS 号或产品分类检索更多品类，获取规格与报价。

常见问题

雷鲁戈利克斯的 CAS 号是多少？

雷鲁戈利克斯的 CAS 号为 737789-87-6。

该产品的纯度和包装规格是什么？

常规纯度规格为按批次COA提供(不公开发布)，包装为按订单/批次确认(不公开发布)，随货提供 COA。

雷鲁戈利克斯有什么用途？

主要应用于医药中间体及原料药。

如何购买或获取报价？

请发送邮件至 info@591daili.com 或通过 WhatsApp 联系，注明产品名称、CAS 号与需求数量，一个工作日内回复报价。供应商：济南圣和化工有限公司。

PubChem 公开数据

Description

Relugolix · CAS 737789-87-6 · C29H27F2N7O5S. UNII P76B05O5V6. LogP: 1.69.

Identification

CAS Registry Number	737789-87-6
PubChem CID	10348973
Molecular formula	C29H27F2N7O5S
IUPAC name	1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
UNII (FDA)	P76B05O5V6

Computed Descriptors

Molecular Weight	623.6
XLogP3	3.2
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	11
Rotatable Bond Count	9
Exact Mass	623.17624448
Monoisotopic Mass	623.17624448
Topological Polar Surface Area	157
Heavy Atom Count	44
Formal Charge	0

Physical & Chemical Properties

LogP	1.69

GHS Hazard Classification

Reported hazard statements	H360 (20%), H361 (60%), H371 (40%), H373 (20%), H411 (20%)

H360 (20%): May damage fertility or the unborn child [Danger Reproductive toxicity]

H361 (60%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

Documented Uses

Relugolix is indicated for the treatment of adult patients with advanced prostate cancer. In a combination product with [estradiol] and [norethindrone], relugolix is indicated for the once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Relugolix is an orally administered, small molecule antagonist of gonadotropin releasing hormone (GnRH) that effectively blocks androgen production and is used to treat advanced prostate cancer. Relugolix therapy may be associated with a low rate of serum enzyme elevations during therapy, but has yet to be linked to instances of clinically apparent acute liver injury.
Breast Feeding; Lactation; Milk, Human; Androgen Antagonists
Relugolix is approved to treat men with:
• Prostate cancer that is advanced.
Take with or without food. Administration with food does not result in any clinically meaningful differences in pharmacokinetics.

Synonyms

Relugolix; 737789-87-6; TAK-385; Orgovyx; TAK 385; TAK385; P76B05O5V6; DTXSID40224167; MYFEMBREE COMPONENT RELUGOLIX; relugolixum; RefChem:57784; DTXCID40146658; MFCD25976856; C29H27F2N7O5S; CHEMBL1800159; Relugolix [USAN:INN]

Frequently Asked Questions

What are the CAS number and molecular formula of Relugolix?

CAS 737789-87-6; molecular formula C29H27F2N7O5S; molecular weight — g/mol.

What other names is Relugolix known by?

Relugolix, 737789-87-6, TAK-385, Orgovyx, TAK 385, TAK385.

Is Relugolix classified as hazardous?

Hazard statements reported: H360, H361, H371, H373, H411.

What are the key physical properties of Relugolix?

LogP: 1.69.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.